Aarti Pharmalabs approves Sept 2026 results; CFO Piyush Lakhani resigns
Aarti Pharmalabs Ltd · Pharmaceuticals & Biotechnology
What the filing says
- Board approved unaudited standalone and consolidated results for the quarter and half year ended 30 September 2026; Gokhale & Sathe LLP gave a limited review
- Consolidated Profit/(Loss) before Tax for the half year ended 30th Sept 2026 was Rs 19,605.02 lakhs
- Piyush Lakhani resigned as CFO and KMP, relieved effective close of business October 30, 2026; Smt. Vibha Thakkar appointed CFO w.e.f. October 31, 2026
Why it's rated major development: the year-on-year change is 180% (50% or more)
Figures checked against the filing by a second AI read, which corrected the first summary. About the business, not the share price.
Original filing
Unaudited Financial Results For The Quarter And Half Year Ended September 30, 2026 - Uploading A Clear Version
Read the filing on BSE (PDF) →Companies guiding to strong growth
Ranked by management's own guidance on revenue and margins — not by us.
Electrical Equipment
Sign up free to see all 6 →
See full rankingsRank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
More from Aarti Pharmalabs Ltd
- Board / shareholder meeting outcomeNotableAarti Pharmalabs Limited announces results of 7th AGM held on September 22, 2026
Other financial results filings this fortnight
- ELANTAS Beck India reports Sep 2026 quarter results, appoints CFO, changes HR role
- IIFL Capital Services Limited announces unaudited Q2 and H1 FY2026-27 results and corporate updates
- Meesho Limited reports unaudited consolidated Q2 and H1 results to September 30, 2026
- Cholamandalam Investment and Finance Company approved Q2 2026 results and QIP proposal
- TVS Motor Company approves Q2 2026-27 results, STPL acquisition and demerger scheme
- Home First Finance Company India Ltd announces Q2 2026 results and CFO appointment
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Summary written by Arthneeti from the company's filing with the stock exchange; check the original filing for full details. Arthneeti is a research and analytics platform, not a SEBI-registered investment adviser, and nothing here is a recommendation to buy or sell.